475 related articles for article (PubMed ID: 29770812)
1. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA.
Han L; Tang C; Yin C
Biomaterials; 2015 Aug; 60():42-52. PubMed ID: 25982552
[TBL] [Abstract][Full Text] [Related]
3. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy.
Sun J; Liu Y; Chen Y; Zhao W; Zhai Q; Rathod S; Huang Y; Tang S; Kwon YT; Fernandez C; Venkataramanan R; Li S
J Control Release; 2017 Jul; 258():43-55. PubMed ID: 28501705
[TBL] [Abstract][Full Text] [Related]
5. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer.
Zhang S; Guo N; Wan G; Zhang T; Li C; Wang Y; Wang Y; Liu Y
J Nanobiotechnology; 2019 Oct; 17(1):109. PubMed ID: 31623608
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
7. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
[TBL] [Abstract][Full Text] [Related]
8. A Tailored DNA Nanoplatform for Synergistic RNAi-/Chemotherapy of Multidrug-Resistant Tumors.
Liu J; Song L; Liu S; Zhao S; Jiang Q; Ding B
Angew Chem Int Ed Engl; 2018 Nov; 57(47):15486-15490. PubMed ID: 30288887
[TBL] [Abstract][Full Text] [Related]
9. Co-Delivery of Doxorubicin and Survivin shRNA-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.
Li Z; Zhang L; Tang C; Yin C
Pharm Res; 2017 Dec; 34(12):2829-2841. PubMed ID: 28948461
[TBL] [Abstract][Full Text] [Related]
10. Photoresponsive Nanovehicle for Two Independent Wavelength Light-Triggered Sequential Release of P-gp shRNA and Doxorubicin To Optimize and Enhance Synergistic Therapy of Multidrug-Resistant Cancer.
Wu M; Lin X; Tan X; Li J; Wei Z; Zhang D; Zheng Y; Zheng AX; Zhao B; Zeng Y; Liu X; Liu J
ACS Appl Mater Interfaces; 2018 Jun; 10(23):19416-19427. PubMed ID: 29771490
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
12. Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy.
Yang H; Shen X; Yan J; Xie X; Chen Z; Li T; Li S; Qin X; Wu C; Liu Y
Biomater Sci; 2018 Aug; 6(9):2426-2439. PubMed ID: 30040100
[TBL] [Abstract][Full Text] [Related]
13. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
14. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
15. Hyperbranched-hyperbranched polymeric nanoassembly to mediate controllable co-delivery of siRNA and drug for synergistic tumor therapy.
Jia HZ; Zhang W; Zhu JY; Yang B; Chen S; Chen G; Zhao YF; Feng J; Zhang XZ
J Control Release; 2015 Oct; 216():9-17. PubMed ID: 26272764
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex.
Han M; Lv Q; Tang XJ; Hu YL; Xu DH; Li FZ; Liang WQ; Gao JQ
J Control Release; 2012 Oct; 163(2):136-44. PubMed ID: 22940126
[TBL] [Abstract][Full Text] [Related]
18. Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.
Yuan Y; Liu J; Yu X; Liu X; Cheng Y; Zhou C; Li M; Shi L; Deng Y; Liu H; Wang G; Wang L; Wang Z
Acta Biomater; 2021 Nov; 135():556-566. PubMed ID: 34496281
[TBL] [Abstract][Full Text] [Related]
19. Self assembled dual responsive micelles stabilized with protein for co-delivery of drug and siRNA in cancer therapy.
Aji Alex MR; Nehate C; Veeranarayanan S; Kumar DS; Kulshreshtha R; Koul V
Biomaterials; 2017 Jul; 133():94-106. PubMed ID: 28433941
[TBL] [Abstract][Full Text] [Related]
20. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
